Liver-restricted type I IFN signature precedes liver damage in chronic hepatitis B patients stopping antiviral therapy
Immune-mediated liver damage is the driver of disease progression in patients with chronic hepatitis B virus (HBV) infection. Liver damage is an Ag-independent process caused by bystander activation of CD8 T cells and NK cells. How bystander lymphocyte activation is initiated in chronic hepatitis B...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2024
|
| In: |
The journal of immunology
Year: 2024, Jahrgang: 212, Heft: 6, Pages: 1002-1011 |
| ISSN: | 1550-6606 |
| DOI: | 10.4049/jimmunol.2300569 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.4049/jimmunol.2300569 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/jimmunol/article/212/6/1002/7927341?login=true 
|
| Verfasserangaben: | Conan Chua, Deeqa Mahamed, Shirin Nkongolo, Juan Diego Sanchez Vasquez, Aman Mehrotra, David K.H. Wong, Raymond T. Chung, Jordan J. Feld, Harry L.A. Janssen, and Adam J. Gehring |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1922501891 | ||
| 003 | DE-627 | ||
| 005 | 20250717005757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4049/jimmunol.2300569 |2 doi | |
| 035 | |a (DE-627)1922501891 | ||
| 035 | |a (DE-599)KXP1922501891 | ||
| 035 | |a (OCoLC)1528044577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chua, Conan |e VerfasserIn |0 (DE-588)1362804746 |0 (DE-627)1922502839 |4 aut | |
| 245 | 1 | 0 | |a Liver-restricted type I IFN signature precedes liver damage in chronic hepatitis B patients stopping antiviral therapy |c Conan Chua, Deeqa Mahamed, Shirin Nkongolo, Juan Diego Sanchez Vasquez, Aman Mehrotra, David K.H. Wong, Raymond T. Chung, Jordan J. Feld, Harry L.A. Janssen, and Adam J. Gehring |
| 264 | 1 | |c March 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Veröffentlicht: 31 January 2024 | ||
| 500 | |a Gesehen am 11.04.2025 | ||
| 520 | |a Immune-mediated liver damage is the driver of disease progression in patients with chronic hepatitis B virus (HBV) infection. Liver damage is an Ag-independent process caused by bystander activation of CD8 T cells and NK cells. How bystander lymphocyte activation is initiated in chronic hepatitis B patients remains unclear. Periods of liver damage, called hepatic flares, occur unpredictably, making early events difficult to capture. To address this obstacle, we longitudinally sampled the liver of chronic hepatitis B patients stopping antiviral therapy and analyzed immune composition and activation using flow cytometry and single-cell RNA sequencing. At 4 wk after stopping therapy, HBV replication rebounded but no liver damage was detectable. There were no changes in cell frequencies at viral rebound. Single-cell RNA sequencing revealed upregulation of IFN-stimulated genes (ISGs) and proinflammatory cytokine migration inhibitory factor (MIF) at viral rebound in patients that go on to develop hepatic flares 6-18 wk after stopping therapy. The type I IFN signature was only detectable within the liver, and neither IFN-α/β or ISG induction could be detected in the peripheral blood. In vitro experiments confirmed the type I IFN-dependent ISG profile whereas MIF was induced primarily by IL-12. MIF exposure further amplified inflammatory cytokine production by myeloid cells. Our data show that innate immune activation is detectable in the liver before clinically significant liver damage is evident. The combination of type I IFN and enhanced cytokine production upon MIF exposure represent the earliest immunological triggers of lymphocyte bystander activation observed in hepatic flares associated with chronic HBV infection. | ||
| 700 | 1 | |a Mahamed, Deeqa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nkongolo, Shirin |e VerfasserIn |0 (DE-588)1081277599 |0 (DE-627)845748629 |0 (DE-576)454092660 |4 aut | |
| 700 | 1 | |a Sanchez Vasquez, Juan Diego |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mehrotra, Aman |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wong, David K H |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chung, Raymond T |e VerfasserIn |4 aut | |
| 700 | 1 | |a Feld, Jordan J |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janssen, Harry L A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gehring, Adam J |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of immunology |d Rockville, Md. : American Association of Immunologists, 1916 |g 212(2024), 6 vom: März, Seite 1002-1011 |h Online-Ressource |w (DE-627)269535217 |w (DE-600)1475085-5 |w (DE-576)079963838 |x 1550-6606 |7 nnas |a Liver-restricted type I IFN signature precedes liver damage in chronic hepatitis B patients stopping antiviral therapy |
| 773 | 1 | 8 | |g volume:212 |g year:2024 |g number:6 |g month:03 |g pages:1002-1011 |g extent:10 |a Liver-restricted type I IFN signature precedes liver damage in chronic hepatitis B patients stopping antiviral therapy |
| 856 | 4 | 0 | |u https://doi.org/10.4049/jimmunol.2300569 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/jimmunol/article/212/6/1002/7927341?login=true |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250411 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1081277599 |a Nkongolo, Shirin |m 1081277599:Nkongolo, Shirin |d 910000 |d 910100 |e 910000PN1081277599 |e 910100PN1081277599 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1922501891 |e 4701680672 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Chua","display":"Chua, Conan","role":"aut","given":"Conan","roleDisplay":"VerfasserIn"},{"family":"Mahamed","display":"Mahamed, Deeqa","role":"aut","roleDisplay":"VerfasserIn","given":"Deeqa"},{"given":"Shirin","roleDisplay":"VerfasserIn","role":"aut","family":"Nkongolo","display":"Nkongolo, Shirin"},{"family":"Sanchez Vasquez","display":"Sanchez Vasquez, Juan Diego","roleDisplay":"VerfasserIn","given":"Juan Diego","role":"aut"},{"role":"aut","given":"Aman","roleDisplay":"VerfasserIn","family":"Mehrotra","display":"Mehrotra, Aman"},{"display":"Wong, David K H","family":"Wong","role":"aut","roleDisplay":"VerfasserIn","given":"David K H"},{"given":"Raymond T","roleDisplay":"VerfasserIn","role":"aut","display":"Chung, Raymond T","family":"Chung"},{"display":"Feld, Jordan J","family":"Feld","role":"aut","roleDisplay":"VerfasserIn","given":"Jordan J"},{"display":"Janssen, Harry L A","family":"Janssen","role":"aut","given":"Harry L A","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Adam J","display":"Gehring, Adam J","family":"Gehring"}],"title":[{"title_sort":"Liver-restricted type I IFN signature precedes liver damage in chronic hepatitis B patients stopping antiviral therapy","title":"Liver-restricted type I IFN signature precedes liver damage in chronic hepatitis B patients stopping antiviral therapy"}],"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"March 2024"}],"relHost":[{"name":{"displayForm":["American Association of Immunologists"]},"language":["eng"],"part":{"text":"212(2024), 6 vom: März, Seite 1002-1011","pages":"1002-1011","issue":"6","extent":"10","year":"2024","volume":"212"},"title":[{"title_sort":"journal of immunology","title":"The journal of immunology"}],"pubHistory":["1.1916 -"],"corporate":[{"display":"American Association of Immunologists","roleDisplay":"Herausgebendes Organ","role":"isb"}],"origin":[{"dateIssuedKey":"2025","publisherPlace":"Oxford ; Bethesda, Md. ; Rockville, Md.","publisher":"Oxford University Press ; Soc. ; American Association of Immunologists","dateIssuedDisp":"2025-"}],"recId":"269535217","id":{"eki":["269535217"],"zdb":["1475085-5"],"issn":["1550-6606"]},"note":["Gesehen am 18.08.2025"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Liver-restricted type I IFN signature precedes liver damage in chronic hepatitis B patients stopping antiviral therapyThe journal of immunology","type":{"bibl":"periodical","media":"Online-Ressource"}}],"name":{"displayForm":["Conan Chua, Deeqa Mahamed, Shirin Nkongolo, Juan Diego Sanchez Vasquez, Aman Mehrotra, David K.H. Wong, Raymond T. Chung, Jordan J. Feld, Harry L.A. Janssen, and Adam J. Gehring"]},"recId":"1922501891","language":["eng"],"note":["Veröffentlicht: 31 January 2024","Gesehen am 11.04.2025"],"id":{"eki":["1922501891"],"doi":["10.4049/jimmunol.2300569"]}} | ||
| SRT | |a CHUACONANMLIVERRESTR2024 | ||